By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Is The FDA Keeping Us Fat?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Is The FDA Keeping Us Fat?
Business

Is The FDA Keeping Us Fat?

JohnCGoodman
JohnCGoodman
Share
3 Min Read
SHARE

Two-thirds of Americans are overweight or obese. A Gallup poll found that 86% of full-time workers are overweight. A report in Health Affairs by Kenneth Thorpe, shows that 7% weight loss in just a small segment of the older adult population (60-64 year olds) could save Medicare as much as $15 billion.

Two-thirds of Americans are overweight or obese. A Gallup poll found that 86% of full-time workers are overweight. A report in Health Affairs by Kenneth Thorpe, shows that 7% weight loss in just a small segment of the older adult population (60-64 year olds) could save Medicare as much as $15 billion. And the savings could be up to $35 billion if those individuals lost 10% of their body weight.

Despite this, last year the FDA rejected three new obesity therapies — Qnexa, Contrave, and Lorqess — the most promising of which, Qnexa, has been shown to bring about sustained weight loss greater than 10% of a person’s body weight. The FDA wanted additional evidence of the drugs were safe and effective in the short term; and evidence showing long-term weight loss. The rub is that the ingredients in two of the three therapies are known to be safe — they’re already FDA approved and widely available for treating migraines, depression, and other conditions. The first of the three drug makers is now going back to try again, having resubmitted its application for FDA approval.

Arguably, the main reason the FDA is hesitant to approve an obesity drug is because it considers nothing as safe for controlling weight as diet and exercise. However, diet and exercise generally fail. And there are few medications available — most of which are ineffective. That leaves surgery, a drastic step for many with a relatively high risk of death.

More Read

Value-Based Purchasing
Changes to Value-Based Purchasing Measures in 2015
Dr. Google, I’d Like You to Meet Google Insurance Co.
Southern California Hospital Offers Appointments for the Emergency Room for $15.00 for Non Emergency Visits-InQuickER
Living in Denial
3 Tips To Improve Your Healthcare Customer Service Team

Without prescription weight-loss drugs, people turn to over-the-counter remedies, many of which are not very safe either. These include highly-caffeinated energy drinks that can raise blood pressure and herbal remedies bought on the Internet, many of which come from China and actually contain active ingredients that have been banned by the FDA.

   

TAGGED:FDAobesitypharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

health Facebook advertising
BusinesseHealthSocial Media

Duke Health and Facebook Advertising Case Study

March 19, 2013
healthcare IT
BusinesseHealthHospital AdministrationPolicy & LawTechnology

5 Questions with Dan Haley, VP of Government and Regulatory Affairs at athenahealth

April 17, 2013
Pew Social Media
BusinesseHealthSocial Media

Engagement: Making Your Social Media Matrix Sticky

January 19, 2014

A High Price for Rare Cancer Drugs

August 31, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?